Viyash Scientific Limited Shareholders Approve Key Appointments and ESOPs
Viyash Scientific Limited shareholders approved four special resolutions via postal ballot. Key approvals include the appointment of Dr. Haribabu Bodepudi as MD & Group CEO, Mr. Rajaram Narayanan as Whole-time Director, and Mr. Srinivas Vasireddy as Whole-time Director (Executive). Options for over 1% of issued capital were also granted.
The appointments of key management personnel and the approval of ESOPs can have a medium-term impact on the company's strategic direction and employee motivation.
The announcement details the approval of key management appointments and the grant of stock options through a shareholder vote, indicating positive progress and shareholder confidence.
Viyash Scientific Limited (formerly Sequent Scientific Limited) announced the results of its postal ballot voting, confirming the approval of four special resolutions by its shareholders. The resolutions passed include the appointment and remuneration of Dr. Haribabu Bodepudi as Managing Director and Group CEO for a two-year term, the appointment of Mr. Rajaram Narayanan as a Whole-time Director, and the appointment of Mr. Srinivas Vasireddy as a Whole-time Director (Executive) for two years.
Additionally, shareholders approved the grant of stock options to an identified employee, representing more than 1% of the company's issued capital within a one-year period. The resolutions were deemed passed on March 12, 2026, which was the last day for remote e-voting. The company provided details of the voting results, showing strong support for all resolutions across promoter, public institutional, and public non-institutional shareholder categories.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under shareholder meetings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.